About the Journal

Download [This article belongs to Volume - 140, Issue - 08]

Abstract : Diabetes mellitus and gout are common morbid diseases. They share the unwanted deleterious effects on renal and cardiovascular systems. The current review aimed to investigate the relationship between diabetes mellitus and hyperuricemia and assess the drugs that tackle both diseases. A systematic electronic search was conducted in the Pub Med including E pub and ahead of print and Google Scholar databases. The search was limited to studies assessing the relationship between gout and diabetes mellitus and investigating the effects of anti-diabetic medications on hyperuricemia and published during the period from 2008 to October 2019 with no limitation for the languages or study type. Three hundred-thirty articles were retrieved; the researchers screened the titles and abstracts for eligibility criteria and removal of duplications. Thirty-four articles fulfilled the inclusion and exclusion criteria. Out of 35 full texts approached, seventeen assessed the relationship between diabetes mellitus and gout, all the studies showed that hyperuricemia is a risk factor for diabetes; also the studies concluded a negative correlation between the glycemic control and gout. Salt glucose co-transporters inhibitors-2 (SGLT-2i), metformin, and pioglitazone reduced serum uric acid. Gout (or hyperuricemia) is a risk factor for diabetes; the effects are stronger in prediabetes and early stages of diabetes. However, poor glycemic control improves hyperuricemia due to diuresis. The best medications for hyperuricemia in patients with type 2 diabetes were SGLT-2 inhibitors. In addition, metformin and pioglitazone are suggested.

Copyright © 2020 All rights reserved | Bulletin of National Institute of Health Sciences